Desai Ami V, Elmuti Lena, Cahaney Christine, De Guzman Raymond M, Streby Keri A, Cohn Susan L
Department of Pediatrics, University of Chicago, Chicago, Illinois, USA.
Department of Radiology, University of Chicago, Chicago, Illinois, USA.
Pediatr Blood Cancer. 2023 Apr;70(4):e30227. doi: 10.1002/pbc.30227. Epub 2023 Jan 31.
Survival for patients with recurrent central nervous system (CNS) neuroblastoma remains poor. A single-institutional study demonstrated the potential of multimodality therapy, including compartmental intrathecal radioimmunotherapy (cRIT) with I-3F8 or I-8H9 to increase the survival of neuroblastoma patients with CNS relapse. However, not all patients are able to receive this therapy. We report three patients with CNS neuroblastoma who remain disease-free 3-9 years after receiving multimodality treatment without cRIT. Additional studies to identify patients most likely to benefit from cRIT are warranted.
复发性中枢神经系统（CNS）神经母细胞瘤患者的生存率仍然很低。一项单机构研究表明，多模式治疗具有潜力，包括使用I-3F8或I-8H9进行鞘内放射免疫治疗（cRIT），以提高中枢神经系统复发的神经母细胞瘤患者的生存率。然而，并非所有患者都能接受这种治疗。我们报告了三名中枢神经系统神经母细胞瘤患者，他们在接受不含cRIT的多模式治疗后3至9年仍无疾病。有必要进行更多研究以确定最有可能从cRIT中受益的患者。
